Guardant Wins Fresh Look at DNA-Tech Patent in $83 Million Case

Guardant Health Inc. convinced the Federal Circuit to toss a US patent tribunal’s decision that upheld a University of Washington DNA-sequencing patent underpinning an $83.4 million infringement verdict against the biotech company, sending the case back for further review.

The Patent Trial and Appeal Board misapplied obviousness law by demanding proof that Guardant didn’t need to provide, since the relevant claimed steps in US Patent No. 10,760,127 were already shown together in an earlier published Pacific Biosciences patent application, Judge Kara F. Stoll wrote in an opinion issued Friday for a three-judge panel at the US Court of Appeals for ...